TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Dose Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV seropositive diagnosed with standard techniques~2. Age for perinatally-acquired HIV/AIDS Group (PA subjects): 5.0 to 24.9 y~3. Age for non-perinatally-acquired HIV/AIDS Group (non-PA subjects): 15.0 to 24.9 y~4. In usual state of good health (no hospitalizations, emergency room or unscheduled acute illness visits for 2 weeks prior)~5. Subject and/or family commitment to the 3-month study~Exclusion Criteria:~1. Other chronic health conditions that may affect growth, dietary intake, and/or nutritional status~2. Pregnancy~3. Participation in another HIV intervention study with impact on 25D serum concentrations~4. Use of vit D supplementation (subjects willing to discontinue supplementation will become eligible after a 2-month washout period)~5. Baseline elevated serum calcium concentration~6. Non-English speaking

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- 4000IU (Type: ACTIVE_COMPARATOR): Subjects in this arm take a daily dose of 4000IU of Vitamin D3
- 7000IU (Type: ACTIVE_COMPARATOR): Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a postmenarchal female subject 12 years and older~* Subject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% Potassium Hydroxide (KOH) in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (≤4.5)~Exclusion Criteria:~* Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)~* Need for systemic and/or topical (vaginal) anti fungal treatment, including prescription or over-the-counter products during the study and treatment for vulvovaginal candidiasis (VVC) 28 days prior to randomization.~* Subject has uncontrolled diabetes mellitus.~* Subject has a vaginal sample with pH \>4.5.~* Subject has a history of or an active cervical/vaginal cancer.

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibrexafungerp (SCY-078) (Type: EXPERIMENTAL): 300 mg BID for one day
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RHA Redensity - Perioral Rhytids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Outpatient, male or female of any race, 22 years of age or older~* Moderate to severe perioral rhytids of grade 2 or 3 on the four-point PR-SRS (ranging from 0-3)~* Willing to abstain from facial aesthetic procedures/therapies that could interfere with study evaluations~* Able to follow study instructions and complete all required visits.~* Sign the IRB-approved ICF, Photographic Release Form and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study- related procedures being performed.~Exclusion Criteria :~* Female subjects that are pregnant, breast-feeding or of childbearing potential and not practicing reliable birth control~* Known hypersensitivity/allergy to any component of the study devices~* Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders~* Clinically significant active skin disease within 6 months~* History of connective tissue disease

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TEOSYAL RHA Redensity (Type: EXPERIMENTAL): Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
- No Treatment (Type: NO_INTERVENTION): No treatment control group (n=52).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PracticeGround: Transforming Training and Delivery of Mental Health EBPs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
PATIENTS~Inclusion Criteria:~* Meets DSM-IV criteria for MDD and/or DD~* Obtains a score of 11 or greater on the PHQ-9~* Currently receiving psychosocial treatment for depression by a study-participant clinician~* Payment-eligible to receive at least 12 weeks of additional psychosocial treatment~Exclusion Criteria:~* Current diagnosis of bipolar disorder or another psychotic disorder~* Active mania~* Current diagnosis of alcohol and/or drug dependence~* At imminent risk of suicide (as deemed by their clinician).~PROVIDERS~Inclusion Criteria:~* English speaker~* 18 years or older~* Currently licensed mental health treatment provider (or a therapist working towards licensure under direct supervision of licensed mental health treatment provider)~* Have an office with access to internet~* Have access to computer with sound card and/or tablet and printer~* Capacity to accept new patients seeking treatment for depressive symptoms~Exclusion Criteria:~* (PILOT ONLY) Receiving training for an evidence based treatment for depression, including behavioral activation, interpersonal therapy, cognitive/cognitive-behavioral therapy, mindfulness-based cognitive therapy or cognitive behavioral analysis system of psychotherapy~* Participated in the Field Test for WILLOW~* Is not comfortable/savvy with technology (by answering I get easily frustrated and usually walk away from it to the question Which response best matches how you typically respond to complicated problems you encounter when using a new app, computer, or technology for the first time?; answering I am not comfortable and/or do not enjoy technology, particularly new forms of technology. I avoid the use of technology as much as is realistically possible. to the question How technologically savvy/skilled are you?)~* Does not have a feasible office set up for using a computer in therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WILLOW (Type: EXPERIMENTAL): Clinicians have access to WILLOW's dynamic progress monitoring, clinical decision support, rich visual displays of client outcomes, online training modules in ESTs, just-in-time training for guided real-time assistance in delivering ESTs, educational videos, and a client portal
- Treatment-as-Usual (Type: ACTIVE_COMPARATOR): Usual care without access to WILLOW.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women will be confirmed as postmenopausal (either natural or surgical) based on cessation of menses for \>1 year.~* Ability to provide informed consent~* Baseline brachial flow-mediated dilation (FMD) \< 6%Δ (rationale: non-invasive screening to ensure exclusion of subjects with exceptionally high baseline endothelial function.~* Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk for 2 min, climb 10 stairs)~* Willing to accept random assignment to condition~Exclusion Criteria:~* Current smoking~* Having past or present alcohol dependence or abuse, as defined by the American Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders~* Body mass index (BMI) \>40 kg/m2 (FMD measurements can be inaccurate in severely obese patients)~* Chronic clinical diseases (e.g., coronary artery/peripheral artery/cerebrovascular diseases, diabetes, chronic kidney disease requiring dialysis, neurological disorders or diseases that may affect motor/cognitive functions \[multiple sclerosis, Parkinson's disease, polio, Alzheimer's disease, dementia or other brain diseases of aging\]), except hypertension and hyperlipidemia~* Regular vigorous aerobic/endurance exercise (\>3 vigorous bouts/week).~* Not weight stable in the prior 3 months (\>2 kg weight change) or unwilling to remain weight stable throughout study (rationale: recent weight change or weight loss can influence vascular function.~* Current treatment or recent cessation (\< 3 mo) of hormone replacement therapy~* Moderate or severe peripheral artery disease (ankle-brachial index \<0.7).~* A graded exercise test will be performed by all subjects, if there is physician concern or an adverse event, the subject will not participate in a maximal oxygen consumption (VO2max) test (this will be determined in accordance with stated contraindications for exercise testing provided by the American Heart Association).~* Thyroid disease that is not controlled by medications or \<3 month's use of a particular medication and/or dosage (uncontrolled thyroid diseases are associated with alterations in vascular function).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- MitoQ (Type: EXPERIMENTAL): MitoQ, 20 mg per day for six weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, inert excipient, one time per day for six weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Total Intravenous Anesthesia vs. Inhalational Anesthesia in Acute Subdural Hematoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients posted for emergency craniotomy with TBI having~  * Subdural hematoma~ * GCS \< 8~ * Age 18 to 60 years.~ * Both males and females~Exclusion Criteria:~* Extradural hematoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group P (Type: ACTIVE_COMPARATOR): Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
- Group I (Type: ACTIVE_COMPARATOR): Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin in Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 55 years old~* MS diagnosis according McDonald criteria~* Relapsing-remitting MS~* EDSS 0 - 6~* Disease activity as occurrence of CEL in brain MRI~* IFN-beta therapy for at least 6 months~Exclusion Criteria:~* Primary chronic progressive MS~* Symptoms and signs of clinical disease conditions similar to MS~* Conditions that can disturb MRI measurements~* Clinically relevant GI diseases eg Colitis ulcerosa, Crohns disease, history of Ulcus pepticum~* Clinically relevant lung, heart, CNS, infectious disease~* Clinically relevant liver, kidney or bone marrow abnormalities (as defined by specific clinical chemistry values)~* Allergies towards Gd-DTPA~* Allergies towards constituents of the therapeutic agent~* Recruitment to other clinical trials within 6 months prior to or during this study~* Pretreatment with complete lymph irradiation, antibody therapy against lymphocyte populations (eg. anti-CD4, Campath-1H), mitoxantrone, cyclophosphamide, cyclosporin A, human antibodies, all immunomodulatory or immunosuppressive agents including recombinant cytokines or other potential experimental MS therapies (6 months prior to study start), glatiramer acetate, azathioprine, IVIg (6 months prior to study start) pregnancy or lactation~* Alcohol or drug abuse~* Inhibitors of Cytochrom P 450 3A (eg. cyclosporin, macrolide antibiotics, azole antimycotics).~* Medical or psychological conditions that could hamper with the patients capacity to understand patient information, to give the informed consent, to adhere to the protocol of the study and to be able to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- interferon (Type: ACTIVE_COMPARATOR): None
- untreated (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed stage III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer~  * Adenocarcinoma~ * Large pelvic mass and/or bulky abdominal disease and/or malignant pleural effusion~ * Pleural effusion only for stage IV (parenchymal, liver, lung, or other distant metastases not allowed)~ * No borderline or low-malignant potential tumors~* Optimal cytoreduction clinically deemed unlikely~* CA 125 at least 70 units/mL~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* SGOT no greater than 2 times ULN~Renal:~* Creatinine clearance at least 50 mL/min~Cardiovascular:~* No congestive heart failure or cardiac arrhythmia~* No myocardial infarction or angina within past 6 months~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No severe gastrointestinal symptoms (i.e., partial obstruction) and/or gastrointestinal bleeding~* No grade 2 or greater sensory neuropathy~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission~* No active or uncontrolled infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for this cancer~Chemotherapy:~* No prior chemotherapy for this cancer~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior pelvic radiation for this cancer~Surgery:~* See Disease Characteristics~* Prior exploratory laparotomy allowed provided an aggressive tumor debulking procedure was not performed (e.g., bilateral salpingo-oophorectomy/total abdominal hysterectomy with omentectomy)~* Prior salpingo-oophorectomy and/or partial omentectomy allowed~Other:~* No other concurrent anti-cancer therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- chemo/debulking surgery/IP chemo (Type: EXPERIMENTAL): neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* Receiving chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease for at least 12 weeks prior to Screening~* Currently maintained on erythropoiesis-stimulating agent therapy, with a dose received within 6 weeks prior to or during Screening~* Mean Screening hemoglobin between 8.0 and 11.0 grams per deciliter (g/dL) (inclusive) in the US and between 9.0 and 12.0 g/dL (inclusive) outside of the US~* Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20% during Screening~Exclusion Criteria:~* Anemia due to a cause other than chronic kidney disease or participants with active bleeding or recent blood loss~* Uncontrolled hypertension~* Red blood cell transfusion within 8 weeks prior to randomization~* Anticipated to recover adequate kidney function to no longer require dialysis~* Severe heart failure at Screening (New York Heart Association Class IV)~* Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure, or stroke within 12 weeks prior to or during Screening~* Hypersensitivity to Vadadustat, Darbepoetin alfa, or any of their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vadadustat (Type: EXPERIMENTAL): None
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All of the following criteria must be met for the potential subject to be eligible for participation:~  1. The subject is 2 to 12 years of age~ 2. The subject's American Society of Anesthesiologists physical status is ASA I or II (see appendix 1).~ 3. The subject is scheduled for elective tonsillectomy with or without adenoidectomy surgery (procedures with myringotomy tube placement are allowed).~ 4. The subject will be hospitalized overnight after surgery~ 5. The subject's parent/legally authorized guardian has given written informed consent to participate; and where applicable, the subject has given appropriate assent to participate.~     Exclusion Criteria:~* The potential subject is NOT eligible for participation if any of the following exclusion criteria apply:~  1. The subject has a history or a family (parent or sibling) history of malignant hyperthermia~ 2. The subject has known significant renal or hepatic disorders determined by medical history, physical examination or laboratory tests.~ 3. The subject has a known or suspected allergy to opioid analgesics~ 4. The subject is a pregnant or lactating female (if post-menarcheal, a negative pregnancy test must be confirmed prior to the planned surgery time (in AMSAC) consistent with current standard of care.~ 5. The subject has history of. cardiovascular issues which would preclude the use of dexmedetomidine, (e.g. Down's Syndrome, dysrhthymias, conditions where hypotension is to be avoided).

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Fentanyl 1 (Type: ACTIVE_COMPARATOR): Fentanyl 1 micrograms (mcg)/kilogram (kg)
- Fentanyl 2 (Type: ACTIVE_COMPARATOR): Fentanyl 2 micrograms (mcg)/kilogram (kg)
- Dex 3 (Type: EXPERIMENTAL): Dexmedetomidine 2 micrograms (mcg)/kilogram (kg)
- Dex 4 (Type: EXPERIMENTAL): Dexmedetomidine 4 micrograms (mcg)/kilogram (kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Trauma-Related Anger in OEF/OIF/OND Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female current or former member of the military (active duty, National Guard or Reserve) Deployed to Iraq or Afghanistan~* Experience trauma during deployment~* Clinically significant anger~* At least 2 additional symptoms of PTSD hyperarousal~* If on medication, no changes within prior 4 weeks~Exclusion Criteria:~* Current severe substance use disorder or prior severe substance use disorder not in remission for at least 3 months~* Current psychotic symptoms~* current Mania or Bipolar Disorder~* Current suicidal or homicidal ideation requiring hospitalization~* Any severe cognitive impairment or history of Organic Mental Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Intervention (CBI) (Type: EXPERIMENTAL): 12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
- Supportive Intervention (SI) (Type: ACTIVE_COMPARATOR): 12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete